Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition 
EASL LiverTree™, Michal Safran, 207342
Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus
EASL LiverTree™, Masaya Sugiyama, 207343
Autophagy-related liver enzymes in chronic liver disease
EASL LiverTree™, Dimitrios Samonakis, 207359
Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis
EASL LiverTree™, Malte Wehmeyer, 207361
Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin
EASL LiverTree™, Pasquale Piccolo, 207362
Refinement of diagnostic criteria and frequency estimation of LPAC syndrome: a French multicenter study
EASL LiverTree™, Dong Catherine, 207363
DIFFERENTIALDIAGNOSTICS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN OF EARLY AGE 
EASL LiverTree™, Galina Volynets, 207377
High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage.
EASL LiverTree™, Claudia Einer, 207379
Prognostic Value of 2D-Shear Wave Elastography(2D-SWE) for staging cirrhosis in chronic liver diseases (CLD) in two severity classes according to liver-related complications
EASL LiverTree™, Priscila Pollo Flores, 207397
Reliability criteria for liver stiffness measurement with ARFI
EASL LiverTree™, Jérôme Boursier, 207398
The ProC3 marker of type III collagen formation accurately reflects hepatic inflammation and fibrosis stage in asymptomatic alcoholic liver disease patients
EASL LiverTree™, Maja Thiele, 207399
Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter
EASL LiverTree™, Valentin Blank, 207414
CT-driven Model for End-Stage Liver Disease: Comparison of Survival Prediction with MELD score
EASL LiverTree™, Ji Eun Lee, 207415
Comparison of T2* and Signal Intensity Ratio Methods for MRI Assessment of Hepatic Iron Overload
EASL LiverTree™, Christopher Kagay, 207418
Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values.
EASL LiverTree™, Emma Robinson, 207432
Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson's disease
EASL LiverTree™, Razvan Iacob, 207435
IsFood-intake a Confusing Factor For Liver Stiffness Evaluation by2D-SWE in Normal Subjects?
EASL LiverTree™, Alina Popescu, 207436
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
EASL LiverTree™, Elton Dajti, 207437
In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma
EASL LiverTree™, Antonio Saviano, 207453
CeO2NPs ARE SIMILARLY EFECTIVE AS SORAFENIB IN INCREASING SURVIVAL IN RATS WITH HCC
EASL LiverTree™, Guillermo Fernández Varo, 207454
Hepatocyte c-Jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice
EASL LiverTree™, Mohamed Ramadan Mohamed, 207455
Chemokine receptor CXCR3 modulates polarization of tumor associated macrophages limiting tumor growth and angiogenesis in murine hepatocellular carcinoma
EASL LiverTree™, Elisa Fabiana Brandt, 207456
Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma
EASL LiverTree™, Yu Rim Lee, 207470
Molecular characterization of autophagic and apoptotic signaling induced by Sorafenib in liver cancer cells: In vitro and in vivo studies
EASL LiverTree™, M. Ángeles Rodríguez-Hernández, 207472
Activated platelets contribute to the progression of hepatocellular carcinoma by altering the immune cell environment
EASL LiverTree™, Natasa Pavlovic, 207474
Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening
EASL LiverTree™, Charlotte Ng, 207490
Canonical inhibition of TransformingGrowth Factor β Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll Like Receptor 7 upregulation.
EASL LiverTree™, Fatma Mohamed, 207492
 S100a11 is part of a whole network of tumor suppressors and oncogenes deregulatedearly with hepatic steatosis and contributing to hepatocellular carcinoma development
EASL LiverTree™, Cyril Sobolewski, 207493
Aspecific ECM composition regulates Smad dependent - TGFbeta1-induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds
EASL LiverTree™, Krista Rombouts, 207508
Analysis of HBV DNA Integration in Tumor and non-Tumor Liver Tissues by a High-Throughput Viral Integration Detection Method.
EASL LiverTree™, Deborah D'Aliberti, 207509
New targets for hepatocellular carcinoma therapy: the Myc/PRMT5/RNAP II circuit
EASL LiverTree™, Cristiana Porcu, 207510
Novel microRNA-based drug CD5-2 reduces liver cancer development in multi-drug-resistance gene-2 knockout mice
EASL LiverTree™, Ken Liu, 207511
The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study
EASL LiverTree™, Cornelius Engelmann, 207526
TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent
EASL LiverTree™, Eihab Al-Herwi, 207527
Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective?
EASL LiverTree™, Seong Hee Kang, 207528
Sub maximally dilated Viatorr CX improves one year survival compared to conventional covered TIPS: a case-control study
EASL LiverTree™, Michael Praktiknjo, 207529
Beta-Blocker use in Cirrhosis is Independently Associated with Minimal Hepatic Encephalopathy
EASL LiverTree™, Jasmohan S Bajaj, 207542
VALIDATION OF THE BAVENO CRITERIA FOR ENDOSCOPIC SURVEILLANCE OF VARICES IN CHOLESTASIC DISEASES
EASL LiverTree™, STEPHANIE TASAYCO, 207543
High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis
EASL LiverTree™, Laura Turco, 207544
Higher in-hospital and post-discharge mortality and hospital charges in cirrhotic patients with acute respiratory illness in the United States
EASL LiverTree™, Pauline Nguyen, 207545
Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis
EASL LiverTree™, ThucNhi Dang, 207558
The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma 
EASL LiverTree™, Hsiao Sheng Lu, 207559
Characteristics of bone marrow drived mesenchymal stem cells in patients with liver cirrhosis
EASL LiverTree™, Ki Tae Suk, 207560
Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in cirrhosis: a systematic review and meta-analysis of randomized controlled trials
EASL LiverTree™, Roger F. Butterworth, 207561
Health care costs are double for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC) who progress to end-stage liver disease (ESLD)
EASL LiverTree™, Rohit Loomba, 207576
High real-world healthcare costs in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) compensated cirrhosis (CC)patients with and without type-2 diabetes mellitus (DM): A large German database study
EASL LiverTree™, Ali Canbay, 207577
Functional polymorphisms of innate immunity receptors are not risk factors for non-SBP type bacterial infections in cirrhosis
EASL LiverTree™, Tamas Tornai, 207578
The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis
EASL LiverTree™, Ji Jade King, 207579
Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience
EASL LiverTree™, Nikolaus Pfisterer, 207594
The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites
EASL LiverTree™, Nikolaus Pfisterer, 207595
Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes
EASL LiverTree™, Marta García Guix, 207597
The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis
EASL LiverTree™, Signe Wiese, 207612
Hepatopulmonary syndrome: a spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients
EASL LiverTree™, Aurelia Chiricuta, 207613
Is obesity an additional negative factor in sarcopenic cirrhotic patients?
EASL LiverTree™, Daria D'Ambrosio, 207614
Liver cirrhosis and wound healing: Activation of von Willebrand factor and platelets
EASL LiverTree™, Lasse Langholm, 207615
Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI
EASL LiverTree™, Maria C. Speranta Iacob, 207629
Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria
EASL LiverTree™, Marcus Maximilian Mücke, 207630
The Indication, Dosage and Duration of Proton Pump Inhibitors in Liver Cirrhosis 
EASL LiverTree™, Marianne De Roza, 207631
the effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients
EASL LiverTree™, Vincenza Di Gregorio, 207632
Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study
EASL LiverTree™, Yijin Wang, 207648
Risk factors of hepatitis E related liver failure: a restrospective case-control study
EASL LiverTree™, Yijin Wang, 207649
The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study
EASL LiverTree™, Yijin Wang, 207650
Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe
EASL LiverTree™, Hartl Johannes, 207651
Conservation and variation of the hepatitis E virus open reading frame 2 proteome
EASL LiverTree™, Shaoshi Zhang, 207666
Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture
EASL LiverTree™, Sandra Ciesek, 207667
Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue
EASL LiverTree™, Sandra Ciesek, 207668
Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses
EASL LiverTree™, Marc Luetgehmann, 207684
Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models
EASL LiverTree™, Julie Lucifora, 207685
Inhibition of Hepatitis Virus X protein (HBx) in HBV-Infected Primary Human Hepatocytes leads to the Reappearance of the Smc5/6 Complex
EASL LiverTree™, Rudolf Beran, 207686
Control of glycokinase activity by the HCV protein NS5A increases lipogenesis
EASL LiverTree™, Olivier Diaz, 207700
Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures
EASL LiverTree™, Yechan Jeong, 207701
FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV
EASL LiverTree™, Patrice André, 207702
Cellular RetinoicAcid-Binding Proteins Regulation of Hepatitis C Virus Infection
EASL LiverTree™, Takeshi Saito, 207703
Are there different profiles in microRNA expression in HBV/HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations?
EASL LiverTree™, Ivana Carey, 207718
Dimerization:  A  structural feature for the protection of Hepatitis E virus capsid protein against trypsinization
EASL LiverTree™, Wenjuan Wei, 207719
The correlations between HBV markers in sera and HBVcccDNA for genotypes
EASL LiverTree™, Takeshi Matsui, 207720
Estrogen receptor R1 and CAD are host factors for HDV replication and antiviral targets
EASL LiverTree™, Eloi VERRIER, 207721
Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection. 
EASL LiverTree™, Elena Perpinan Mas, 207738
Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver
EASL LiverTree™, Shingo Nakamoto, 207739
Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort
EASL LiverTree™, Kristopher Bennett, 207742
Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States 
EASL LiverTree™, George Cholankeril, 207755
Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis
EASL LiverTree™, Astrid Marot, 207756
Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis
EASL LiverTree™, Astrid Marot, 207757
Prevalence of alcoholic steatosis in the general adult Portuguese population
EASL LiverTree™, Jorge Leitao, 207759
The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death
EASL LiverTree™, Ulrich Bang, 207772
miRNA regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease
EASL LiverTree™, Adam Kim, 207773
The correlation of obesity with morbidity and mortality in alcoholic hepatitis. 
EASL LiverTree™, yasir yasiralazzawi, 207774
Serum metabolic profiling for the identification of patients with severe alcoholic hepatitis
EASL LiverTree™, Adelina Horhat, 207775
Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort
EASL LiverTree™, Naim Alkhouri, 207790
Increased gut permeability is associated with oxidative stress in patients with NAFLD
EASL LiverTree™, Francesco Baratta, 207791
Increasing Trend forHepatocellular Carcinoma (HCC) Linked to Nonalcoholic Fatty Liver Disease(NAFLD) in the United States
EASL LiverTree™, Ethan Miller, 207792
Non-alcoholic fatty liver disease in non-obese young adults
EASL LiverTree™, Yaakov Maor, 207793
Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease
EASL LiverTree™, Thomas Karlas, 207808
Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study
EASL LiverTree™, Won Kim, 207809
Plasma cells in non-alcoholic steatohepatitis correlates with disease activity
EASL LiverTree™, Mehul Lamba, 207810
Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link?
EASL LiverTree™, Davide Roccarina, 207811
Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study
EASL LiverTree™, Veeral Ajmera, 207824
Role of nutritional intake on clinical presentation of lean and overweight NAFLD
EASL LiverTree™, Rosa Lombardi, 207825
Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children
EASL LiverTree™, Anna Mantovani, 207826
Change of microbiota in patients with improved fatty liver and obesity
EASL LiverTree™, Sang Bong Ahn, 207828

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings